Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-372-6 | CAS number: 98730-04-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 February 1986 to 28 March 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP study compliant with test guidelines of the time. However, current guidelines for prenatal developmental toxicity require an extended dosing period - from implantation to termination. Available as unpublished report, adequate for assessment although only minimal maternal toxicity seen at highest dose tested.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1981 (current guideline adopted 2001)
- Deviations:
- yes
- Remarks:
- does not meet current guideline specification
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-3 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1982 (current guideline adopted 1998)
- Deviations:
- yes
- Remarks:
- does not meet current guideline specification
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,2-dichloro-1-[(3R)-3-methyl-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethan-1-one; 2,2-dichloro-1-[(3S)-3-methyl-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethan-1-one
- EC Number:
- 619-372-6
- Cas Number:
- 98730-04-2
- Molecular formula:
- C11H11Cl2NO2
- IUPAC Name:
- 2,2-dichloro-1-[(3R)-3-methyl-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethan-1-one; 2,2-dichloro-1-[(3S)-3-methyl-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethan-1-one
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: Approximately 17 weeks
- Weight at gestation day 0: 3.21-3.98 kg
- Housing: Individually in elevated stainless steel cages
- Diet: Purina Certified Rabbit Chow ® #5322 ad libitum
- Water: Tap water ad libitum
- Acclimation period: 3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature: 70-76°F
- Humidity: 18-55%
- Air changes (per hr): Not reported
- Photoperiod: 12 hrs dark / 12 hrs light
IN-LIFE DATES: From: 24 February 1986 To: 28 March 1986
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: distilled water containing 0.5% carboxymethylcellulose and 0.1% Tween 80
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Fresh preparations were made weekly and stored under refrigeration. The dose volume was 1 mL/kg body weight on day 7 of gestation. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Prior to initiation, samples were taken to determine homogeneity. Day 0 and day 7 stability analyses were performed on the vehicle, low and high dose dosing solutions. Freshly prepared samples of all dose levels from the first and last mixed batches were analysed for achieved concentration.
The dosing preparations were found to be stable (95-101% of target on day 7), homogeneous (91.9-103% of target) and the achieved concentrations ranged from 94.6-108% of target. - Details on mating procedure:
- Artificial insemination
- Duration of treatment / exposure:
- 13 days, gestation days 7-19 inclusive
- Frequency of treatment:
- Once daily
- Duration of test:
- 29 days, gestation days 0-29
- No. of animals per sex per dose:
- 15 mated females
- Control animals:
- yes, concurrent vehicle
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: days 0, 7, 9, 11, 15, 20, 24 and 29
BODY WEIGHT: Yes
- Time schedule for examinations: days 0, 7, 9, 11, 15, 20, 24 and 29
FOOD CONSUMPTION: Yes
Time schedule for examinations: days 0, 7, 9, 11, 15, 20, 24 and 29
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 29
- Macroscopic examination: main organs of the thoracic, pelvic and abdominal cavities - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - Body weight and sex: Yes: all per litter
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: all per litter
- Skeletal examinations: Yes: all per litter
- Head examinations: Yes: all per litter
- Classification of foetal observations: Yes - Statistics:
- Levene's test of homogeneity of variances initially. Homogeneous data were then analysed using one-way ANOVA; heterogeneous data were transformed where possible. When ANOVA was significant Dunnett's t-test was used to compare each group with the control. The Terpstra-Jonckheere nonparametric test for trend was performed on homogeneous and heterogeneous data. The Cochran-Armitage test for linear trend followed by the Fischer-Irwin 'exact' test was used for the percent of total foetuses and litters with a particular skeletal variant.
- Indices:
- Mean implantation efficiency
- Historical control data:
- Yes
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
No treatment-related effects on maternal body weight.
62.5 mg/kg bw/day: food consumption significantly decreased between days 11 to 15 of gestation.
No treatment-related macroscopic changes observed at necropsy.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 12.5 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 62.5 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
62.5 mg/kg bw/day: lower mean foetal body weight (not significant when litter size used as the covariate in the analysis). The incidence of foetal external, soft tissue or skeletal variations was not treatment-related nor was the incidence of foetal external or soft tissue malformations. Eight foetuses with skeletal malformations at the highest dose were not clearly treatment-related due to the findings being consistent with those found in historical control data.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 62.5 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Table 1 Group Mean Maternal Body Weight Change (g) During Gestation
Days |
Dose level (mg/kg bw/day) |
||||
0 |
0.5 |
2.5 |
12.5 |
62.5 |
|
0-7 |
0.14 |
0.14 |
0.09 |
0.13 |
0.16 |
7-20 |
0.16 |
0.08 |
0.16 |
0.17 |
0.06 |
20-29 |
0.11 |
0.13 |
0.05 |
0.08 |
0.17 |
0-29 |
0.41 |
0.36 |
0.31 |
0.38 |
0.43 |
7-29 |
0.27 |
0.21 |
0.22 |
0.25 |
0.27 |
No statistically significant differences
Table 2 Group Mean Food Consumption (g) During Gestation
Days |
Dose level (mg/kg bw/day) |
||||
0 |
0.5 |
2.5 |
12.5 |
62.5 |
|
0-7 |
1192 |
1220 |
1112 |
1274 |
1187 |
7-9 |
360 |
359 |
329 |
365 |
297 |
9-11 |
315 |
324 |
308 |
325 |
267 |
11-15 |
561 |
506 |
556 |
585 |
373* |
15-20 |
777 |
673 |
758 |
731 |
604 |
20-24 |
608 |
551 |
543 |
539 |
591 |
24-29 |
515 |
482 |
431 |
453 |
634 |
P< 0.05 * statistically significant difference from control
Table 3 Group Mean Litter data
|
Dose level (mg/kg bw/day) |
||||
0 |
0.5 |
2.5 |
12.5 |
62.5 |
|
No. pregnant females |
14 |
13 |
14 |
14 |
13 |
No. corpora lutea |
11.1 |
11.2 |
10.7 |
11.6 |
13.2 |
No. implantations |
7.4 |
7.6 |
6.1 |
7.9 |
8.8 |
% mean implantation efficiency |
66.6 |
66.6 |
59.2 |
67.4 |
67.8 |
No. live foetuses |
6.7 |
6.6 |
5.9 |
7.1 |
8.3 |
% males |
41.5 |
56.0 |
42.4 |
44.8 |
55.1 |
Foetal weight (g) - covariate adjusted |
46.2 |
46.8 |
45.8 |
46.7 |
46.1 |
No statistically significant differences
Table 4 Group Mean Foetal Observations
|
Dose level (mg/kg bw/day) |
|
|||
0 |
0.5 |
2.5 |
12.5 |
62.5 |
|
No. litters examined |
14 |
13 |
14 |
14 |
13 |
No. foetuses examined |
95 |
86 |
82 |
99 |
108 |
No. foetuses with external variations |
0 |
1 |
0 |
0 |
0 |
No. foetuses with external malformations |
0 |
0 |
0 |
0 |
1 |
No. foetuses with soft tissue variations |
7 |
7 |
5 |
6 |
5 |
No. foetuses with soft tissue malformations |
2 |
1 |
0 |
0 |
0 |
No. foetuses with skeletal variations |
69 |
65 |
49 |
73 |
68 |
No. foetuses with skeletal malformations (% foetuses) |
2 (2.1) |
3 (3.5) |
3 (3.7) |
4 (4.0) |
8 (7.4) |
No statistically significant differences
Applicant's summary and conclusion
- Conclusions:
- Administration of 62.5 mg/kg bw/day CGA154281 to pregnant rabbits during the period of organogenesis resulted in minimal maternal toxicity (a small, transient reduction in food consumption). The NOAEL for maternal toxicity was therefore 12.5 mg/kg bw/day. The NOAEL for developmental toxicity and teratogenicity was 62.5 mg/kg bw/day
- Executive summary:
The study was designed to evaluate the developmental toxicity and teratogenic potential of benoxacor (CGA154281 technical) in rabbits. The test material was administered orally at 0.5, 2.5, 12.5 or 62.5 mg/kg bw/day during the period of organogenesis (days 7-19 of gestation). On gestation day 29, the dams were terminated and caesarean sections performed. Live foetuses were weighed and examined for external, soft tissue and skeletal malformations and variations.
The only effect of treatment at the highest dose of 62.5 mg/kg bw/day, was a small reduction in maternal food consumption during the dosing period. There was no clear evidence of developmental toxicity at this dose level and no evidence of teratogenicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
